Clinical Trial Update: PROFAST Intervention in Precursor Multiple Myeloma [NA]

View source ↗

Summary

A Dana-Farber Cancer Institute trial evaluating the PROFAST intervention in precursor states to multiple myeloma has completed (NCT05565638).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Smoldering Waldenström Macroglobulinemia

Drugs mentioned

• PROFAST

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cancer Prevention, Weight Loss | NA | Status: COMPLETED